Off-Label Treatment Approaches for Alopecia Areata

Alopecia areata presents clinicians and their patients with significant challenges in balancing risk and benefit, particularly as it pertains to the uncertainty of several available treatments with respect to safety, accessibility and long-term outcomes. While off-label prescribing of numerous medications is frequently both indicated and necessary to address the varied presentations and degrees of hair loss experienced by patients with alopecia areata, such therapies are often associated with various trade-offs, including uncertainty of potential risk, complicated monitoring and management of side effects, problems with reimbursement and unequal access to affected patients. Most importantly, there is a paucity of evidence from real-world clinical practice that can guide the development of clinical guidelines and informed shared decision-making for affected patients. It will require the contributions of many stakeholders, including clinicians, payers, industry representatives, patient advocates and patients themselves to continue to explore the evidence-based management of alopecia areata in order to establish a safe, effective and fair system of care.

Why It Matters

Alopecia areata is a severe and debilitating medical condition that is not life threatening. Although it can cause significant emotional upset, the condition can go into remission. It can start as small patches of hair loss, progressing to larger patches of hair loss on the scalp, or even complete hair loss on the body. Sufferers, and often their families, experience significant distress caused by the unpredictable nature of the condition, which can lead to feelings of anxiety, sadness and depression. It can also prevent people from engaging in everyday activities as they feel self-conscious about their appearance. Alopecia areata affects not only children but also adults in the workplace and in positions of public life. Sufferers may include entertainers, newscasters, television presenters, celebrities, politicians, sportsmen and women. Family members of children and adolescents with alopecia areata, such as parents and siblings, are also affected by the condition.

Even approved medications cannot reach the intended patients for various reasons, and therefore, off label or “unapproved” use of medications becomes the norm. Janus kinase inhibitors are no exception. While labeling restrictions may limit use to certain age groups or severity of disease in some indications, there are no restrictions in other indications. Other barriers to use include cost, prior authorization, and use of specialty pharmacy as well as office or hospital capacity constraints. Many regions have a dearth of dermatology medical services and long travel time and expense to see a dermatology specialist. Consequently, dermatologists rely on “old standbys” that are used off label for common cutaneous disorders in their everyday practice. Intralesional corticosteroids, topical, and systemic immunotherapies, and systemic immunomodulators are among the common off label agents.

It is important to be aware of the safety considerations of all medications used off label and to counsel and monitor accordingly. Intralesional corticosteroids are a cheap and effective treatment for small patches of onycholysis secondary to distal psoriatic dermatitis. However, repeated use can lead to skin atrophy, localized tissue depression, telangiectasia and pain. Intralesional steroids or even systemic steroids may be used to promote rapid nail regrowth in severe onycholysis.

Topical, oral and parenteral methotrexate have been used to treat more widespread nail psoriasis. Similarly, oral cyclosporine has been used off label for severe psoriatic nail disease. Both are effective in reducing inflammation although as with all potent medications, they require monitoring of liver toxicity, effects on blood counts, risk of and monitoring of kidney toxicity and effects on blood pressure. There are several reported cases of the use of two drugs indicated for treatment of severe skin manifestations resulting from immune activation that may be effective for treating severe alopecia areata. Oral tofacitinib and ruxolitinib (although ruxolitinib is not currently FDA approved for any indication in the US and therefore is used off label) have been reported to induce hair growth with possible side effects of infection (for which patients on these medications may require pretreatment screens and periodic monitoring of lipids and liver enzymes). Topical agents such as minoxidil and anthralin as well as contact immunotherapy (diphenylcyclopropenone and squaric acid dibutyl ester) have been reported to induce hair growth but may result in unpredictable efficacy and have the potential to cause permanent pigment changes, severe dermatitis, or even worsen existing skin disease in some individuals, in addition to causing irritant contact dermatitis.

The health system impact includes the effects of payers that restrict coverage for off label use of a variety of medications for psoriasis, thereby passing costs on to patients and shifting the work of health care clinicians from treatment of the psoriasis to documenting that evidence exists showing a particular medication to be efficacious for a particular indication as well as documenting failures of step therapy policies. Health systems are needed to ensure that there are laboratories available to monitor safety as well as to ensure that all health care professionals including pharmacists are knowledgeable about the commonly used medications to treat psoriasis and are able to counsel their psoriasis patients accordingly. Specialty pharmacies may also create disparities among patients that exist within different geographic locations. The patient who is under-resourced living in a rural location or elsewhere in the country may have to wait longer for access to newer safer treatments for psoriasis, and settle for less effective older medications.

For off label use of these medications, evidence gaps exist for several of them, therefore shared decision making is critical. For many of these treatments, there is a paucity of high quality evidence, particularly long term data on key outcomes such as relapse rates and duration of remission. Recurrence of disease after cessation of therapy is also a problem for many of these treatments. Preparing patients with realistic expectations for their treatment and having a plan for stopping or de escalating can help prevent frustration and optimize results. Personalized treatment plans help optimize patient satisfaction with therapy, by weighing factors including age, pattern of disease, medical comorbidities (e.g. atopic dermatitis, thyroid disease), goals of therapy (e.g. eyebrow vs eyelash), and tolerance of side effects. Finally, informed consent should be documented, plans for monitoring side effects shared with and agreed upon by the physician and patient, side effects prevented or managed, and a plan for alternative therapies and for de escalating existing therapies put in place.

While individual safety is a major concern when medications are prescribed “off label,” there are also larger system-wide implications. These include impacts on payers, on patients’ and families’ out-of-pocket expenses, on requirements for prior authorization, on specialty pharmacy benefit management, and on potential shortages of the new medications. Other implications relate to variations in clinical practice between different regions and between different settings of care, and the need for training of the health care workforce. Administering these new medications will require integration into the existing health system, which will demand coordination with physicians and staff from a variety of disciplines, including dermatology, primary care, and mental health. There also may be implications for monitoring of laboratory tests and reporting of effects on patients.

Who It Affects

Alopecia areata treatment is directed towards inducing hair re-growth of patchy hair loss. For individuals with minimal patchy disease, a rapid and easily administered therapy is typically desired. For individuals with extensive or rapidly progressive hair loss, systemic therapy may be required. Infiltrated areas of alopecia areata are treated with intralesional triamcinolone as first line therapy for individuals with limited disease. For individuals with alopecia areata with moderate to extensive hair loss, topical medications including minoxidil, anthralin and high potency topical corticosteroids can promote hair re-growth and prevent further patch development. For widespread disease including total and universal alopecia, oral immunomodulators or contact immunotherapy can be used alone or in addition to topical therapy. The choice of therapy is based on patient goals, tolerance of side effects and symptoms and degree of compliance with medical management and frequent follow-up.

Children and adolescents with vitiligo are often difficult to manage because of limited information and significant psychosocial component. Off-label topical agents are generally considered first-line therapy for vitiligo due to the potentially serious side effects of injectable and systemic therapies and the fact that most injectable vitiligo treatments are very uncomfortable for children. Contact immunotherapy can be effective for select pediatric patients but typically requires expertise to administer and vigilant follow-up. Approved systemic vitiligo medications have age restrictions; therefore, treating physicians and families must weigh the potential benefits of off-label use in children against the unknown long-term side effects. Children’s school environments, bullying, and activities such as sports or music and dance can significantly affect family decisions and perceptions about vitiligo treatment. Counsel patients on makeup, wigs, and other ways to manage body image changes, so patients do not feel that cancer defines them and can maintain their sense of self esteem throughout cancer treatment.

Management of the patient with alopecia areata who has an inflammatory or autoimmune disorder can be particularly challenging. Many of these conditions (e.g. atopic dermatitis, vitiligo, thyroid disease) are more common in patients with alopecia areata, and some of these individuals may be taking immunomodulators for management of their concurrent condition. Consequently, the treatment of alopecia areata must be considered in the context of concurrent disease, and every effort made to select the optimal therapeutic approach with the least potential for adverse effects. The physician must also be able to manage vaccine schedules, detect subtle signs of infection, and be aware of potential drug interactions. In such cases, input from colleagues in fields such as allergy and immunology, endocrinology, and primary care is particularly helpful in co-ordinating the care of the patient and avoiding unnecessary duplication of monitoring.

Management of skin disease in the pregnant or lactating patient, or patient planning pregnancy, differs from management of the skin disease in other patients. Methotrexate is contraindicated in pregnancy and appropriate precautions regarding contraception and washout periods should be employed. The use of other systemic agents such as cyclosporine and systemic steroids may be considered after thoughtful risk-benefit assessment. While many patients are hesitant to use medications in pregnancy and lactation and thus may resort to topical agents and non-pharmacologic management for symptom control, an understanding of the patient’s family planning timeline and shared decision making can help avoid abrupt cessation of effective therapy and the anxiety associated with it.

Some people may require alternative treatments for ringworm of the scalp, such as people at risk of infection (e.g. healthcare workers) or those with a serious chronic medical condition. Patients with active chronic liver or kidney disease, uncontrolled high blood pressure (hypertension), diabetes, a history of thromboembolic events or recurrent serious infections may not be suitable for some treatments. For such patients alternative local treatments for skin and scalp lesions, cosmetic camouflage and psychological counselling may be offered. However, if systemic treatment is indicated appropriate management and monitoring and close liaison with the relevant specialist(s) will be necessary.

Providers from specialists to generalists in urban and rural settings will be needed to interpret data, monitor for side effects and manage paperwork. While the dermatologist will be the “captain of the team”, primary care providers, pediatricians, nurses and pharmacists will be involved in screening, safety labs and counseling as well as adherence support. Generalists in under-resourced practices may initiate off label treatment and continue until specialty input is sought. Providers will use protocols, manage variability, and make best possible decisions using standardized safety lab panels and patient education materials. Teledermatology can not only increase access to specialty evaluation and management but can also be used as a tool for triage to rapidly evaluate lesions and reduce wait time and travel for families.

Payers, employers and health systems all play a role in influencing real world access at scale to products. Decisions made by these stakeholders around insurance coverage, pharmacy benefit design and formulary composition – in particular whether a product will be affordable for patients and deemed appropriate for use for certain patient populations – can delay therapy. Employers and providers can pressure payers to provide fair coverage of evidence based off label uses. Employers that sponsor a payer’s health plan can be strong advocates for access to particular uses of a product. Additionally, health systems can play an important role in ensuring that patients and their families receive value from expensive cancer therapies by investing in integrated evidence based care pathways to help mitigate the negative impacts of cancer and cancer therapy on daily function and quality of life through strategies to manage mental health and case management. We need government and professional organizations to clarify the amount and type of evidence needed for off label, reimbursement as well as on going registries to capture safety and efficacy.

• Adopt a structured shared decision framework whenever off label therapy is considered. Begin with a clear summary of the diagnosis, disease severity, and goals of care such as faster hair regrowth, reduced new patches, or eyebrow and eyelash recovery. Provide balanced explanations of likely benefits, side effects, monitoring needs, and what is unknown for each option. Document informed consent in simple language. Agree on a trial period, objective checkpoints such as Severity of Alopecia Tool scores or standardized photos, and stopping rules if targets are not met or adverse effects appear.
• Use practical, safety first clinical workflows to reduce risk and variation. Before systemic therapy, perform a standardized safety screen that includes history of infections, vaccination status, pregnancy intentions, thromboembolism risk, and baseline mental health. For agents with systemic immunomodulatory effects, obtain baseline complete blood count, liver enzymes, lipid profile, kidney function, and tuberculosis and hepatitis screening where appropriate. Schedule labs at consistent intervals and define thresholds for dose adjustments or therapy holds. Encourage patients to report fever, persistent cough, new rashes, or visual changes promptly. Provide written instructions for missed doses and clinic contacts.

• Start with the least systemic exposure needed and escalate thoughtfully. For limited patchy disease, prioritize intralesional corticosteroids and topical therapies, then consider contact immunotherapy if needed. For extensive or rapidly progressing disease, weigh systemic options while planning the shortest effective course. Consider combination strategies that allow dose minimization, such as topical minoxidil with contact immunotherapy or low dose systemic agents plus targeted injections. When stopping or tapering, prepare patients for the possibility of relapse and plan follow up windows to address early regrowth loss.
• Improve access and equity through standardized authorization pathways and care coordination. Health systems and payers can agree on clear criteria for evidence based off label uses, including disease severity definitions, prior treatment attempts, and monitoring plans. Design rapid access pathways for patients with urgent need, such as those with rapid progression or severe psychosocial impact. Expand telehealth and nurse led clinics to deliver injections, contact immunotherapy, and monitoring closer to where patients live. Support transportation and scheduling flexibility for working families and students.
• Strengthen guidance with practical, front line recommendations from professional societies. Clinicians benefit from living guidance that ranks off label options by scenario, outlines dosing and monitoring, and provides decision aids for adults and children. Toolkits should include lab schedules, consent templates, photo guides, and strategies for transitions to or from approved therapies. Guidance should also address special populations including pregnant patients, adolescents, and those with multiple autoimmune conditions.
• Invest in real world data and registries to close knowledge gaps. Longitudinal registries and observational programs that track safety, durability of response, relapse after discontinuation, and patient reported outcomes are critical. Consistent measures such as SALT scores and quality of life scales enable meaningful comparisons. Inclusion of diverse populations and community settings improves generalizability. Data sharing between centers and across regions helps payers and policymakers align coverage with the best available evidence and reduces reliance on anecdote.
• Prioritize mental health support as a routine part of care. Normalize screening for anxiety and depression, offer counseling or peer support resources, and include caregivers and families in education. Provide practical supports such as guidance on wigs, scalp care, and eyebrow or eyelash camouflage. Emphasize that hair loss is not the patient’s fault and that emotional reactions are valid. Integrating mental health services into dermatology and primary care visits can reduce stigma and increase uptake.
• Prepare for a future where innovation grows but access remains a separate challenge. New approvals may reduce some off label prescribing, but affordability, supply, and regional capacity will still shape real world care. Stewardship means using effective therapies responsibly, avoiding unnecessary systemic exposure, and ensuring monitoring keeps pace. Policymakers and payers can translate scientific advances into population level benefit by supporting fair coverage, transparent prior authorization, and outcome based reimbursement pilots.
• Put practical steps into action today with a simple checklist. Define goals and expected timelines, select the least systemic option that fits the goals, document consent and monitoring, schedule follow ups and photo tracking, set stopping rules and backup plans, and link patients with mental health and peer support. Communicate with primary care and relevant specialists about the plan, the lab schedule, and warning signs that should trigger outreach. Reassess every few months to ensure the plan still matches patient values and life circumstances.

What Changes

References:

https://pmc.ncbi.nlm.nih.gov/articles/PMC12937895/